German pharmaceutical company BioNTech reported a net profit of 1.13 billion euros (USD 1.37 billion) in the first quarter of this year on the back of strong revenues from its coronavirus vaccine.
The company’s estimated revenues surged to over 2 billion euros for the period from January to March, compared with just 28 million euros in the same period last year.
BioNTech developed the first widely used vaccine against COVID-19 together with US partner Pfizer, which holds the market and distribution rights in much of the world.
The Mainz-based company said its revenues included over 1.75 billion in gross profits from vaccine sales in Pfizer’s territories, and almost 200 million from sales to customers in its region.
BioNTech shares rose by more than 8 per cent to USD 198.55 in pre-market trading on Nasdaq Monday.
The results are a significant turnaround for the company, which made a net loss of 53 million euros in the first quarter of 2020.
Early last year as the pandemic began, BioNTech pivoted from researching treatments for cancer to developing a vaccine against COVID-19. Like its rival Moderna, the company’s vaccine uses mRNA technology to prime the body’s immune system to attack the virus.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.